0000950170-24-026001.txt : 20240305 0000950170-24-026001.hdr.sgml : 20240305 20240305162627 ACCESSION NUMBER: 0000950170-24-026001 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240301 FILED AS OF DATE: 20240305 DATE AS OF CHANGE: 20240305 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brandenberger Ralph CENTRAL INDEX KEY: 0001853197 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39370 FILM NUMBER: 24720915 MAIL ADDRESS: STREET 1: 6000 SHORELINE COURT, SUITE 102 CITY: SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Nkarta, Inc. CENTRAL INDEX KEY: 0001787400 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 474515206 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1150 VETERANS BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: (925) 407-1049 MAIL ADDRESS: STREET 1: 1150 VETERANS BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 ownership.xml 4 X0508 4 2024-03-01 0001787400 Nkarta, Inc. NKTX 0001853197 Brandenberger Ralph C/O NKARTA, INC. 1150 VETERANS BOULEVARD SOUTH SAN FRANCISCO CA 94080 false true false false Chief Technical Officer false Common Stock 2024-03-01 4 M false 3808 3.89 A 85384 D Common Stock 2024-03-01 4 M false 2955 3.89 A 88339 D Common Stock 2024-03-01 4 S false 8367 12.51 D 79972 D Stock Option (right to buy) 3.89 2024-03-01 4 M false 3808 0.00 D 2029-09-05 Common Stock 3808 22445 D Stock Option (right to buy) 3.89 2024-03-01 4 M false 2955 0 D 2029-09-05 Common Stock 2955 25629 D The transaction reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person and most recently amended on September 2, 2022. This transaction was executed in multiple trades at prices ranging from $12.50 to $12.58. The price reported above reflects the weighted average price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. The options exercised were fully vested. The options exercised were fully vested. Unvested options will vest and become exercisable ratably in monthly installments until fully vested on July 1, 2024. /s/ Alicia Hager, as Attorney-in-Fact 2024-03-05